Form 4: RxSight Executive Eric Weinberg Acquires 92,200 Stock Options

Chief Commercial Officer Eric Weinberg of RxSight, Inc. was granted 92,200 stock options on March 4, 2024.

Summary

• Eric Weinberg, Chief Commercial Officer of RxSight, Inc., filed a Form 4 on March 6, 2024.
• The filing reports the grant of 92,200 stock options on March 4, 2024, at an exercise price of $56.07.
• These options vest monthly over a four-year period, starting from March 4, 2024, contingent upon continued service with the company.
• Following the transaction, Weinberg directly owns 92,200 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Industry Context

Stock option grants are a common form of executive compensation in the technology and healthcare industries, used to attract and retain talent and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like RxSight's.
• The vesting schedule of 1/48th per month is a typical vesting arrangement, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies in the medical device space, such as STAAR Surgical or Glaukos, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the executive to improve company performance and increase shareholder value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.

Key Dates